(19)
(11) EP 2 239 669 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.12.2015 Bulletin 2015/50

(45) Mention of the grant of the patent:
09.09.2015 Bulletin 2015/37

(21) Application number: 10171001.0

(22) Date of filing: 31.12.2002
(51) International Patent Classification (IPC): 
G06F 17/30(2006.01)

(54)

Pharmaceutical compounding information management system

Verwaltungssystem für pharmazeutische Zusammensetzungsinformationen

Système de gestion d'informations relatives à la formulation pharmaceutique

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

(30) Priority: 31.12.2001 US 344869 P

(43) Date of publication of application:
13.10.2010 Bulletin 2010/41

(62) Application number of the earlier application in accordance with Art. 76 EPC:
02796129.1 / 1461729

(73) Proprietor: B. Braun Medical, Inc.
Bethlehem PA 18018-0027 (US)

(72) Inventors:
  • DiGianfilippo, Aleandro
    Scottsdale, AZ 85262 (US)
  • Pierce, Richard F.
    Glendale, AZ 85308 (US)

(74) Representative: Winter, Brandl, Fürniss, Hübner, Röss, Kaiser, Polte - Partnerschaft mbB 
Patent- und Rechtsanwaltskanzlei Bavariaring 10
80336 München
80336 München (DE)


(56) References cited: : 
GB-A- 1 273 640
US-A- 4 333 356
 JP-A- 58 070 079
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).